Anti-PD-L1 monoclonal antibody (specialist)
Durvalumab
Brand names: Imfinzi
Adult dose
Dose: 1500mg IV q3w or q4w; weight-based 10mg/kg q2w (per indication)
Route: IV
Frequency: q2–4w
Clinical pearls
- Multiple NICE TAs: stage III unresectable NSCLC after CRT (PACIFIC), ES-SCLC (with chemo), biliary tract, hepatocellular, urothelial
- ESMO Immuno-oncology toxicity guidelines
- SACT-funded; specialist oncology only
Contraindications
- Active autoimmune disease (relative)
- Solid organ transplant (relative)
- Hypersensitivity
Side effects
- Immune-related adverse events: pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatitis, myocarditis, neurological
- Infusion reactions
- Fatigue
Interactions
- Systemic corticosteroids (avoid prophylactic; use to manage irAEs)
Monitoring
- TFTs
- Cortisol
- LFTs
- Renal
- Glucose
- irAE symptoms each cycle
Reference: BNF; multiple NICE TAs; ESMO IO toxicity guidelines; SmPC; https://bnf.nice.org.uk/drugs/durvalumab-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina